Revision as of 23:41, 28 May 2024

Back to Top

Section editor
	Talal Hilal, MD Mayo Clinic Phoenix, AZ, USA

Unlike the other chemotherapy regimen pages, this one is not disease-specific. Rather, this is meant to be a gathering point for all stem cell mobilization regimens.

11 regimens on this page 13 variants on this page

Stem cell mobilization, all lines of therapy

These are regimens intended to mobilize stem cells, very incomplete right now but will be filled in over time.

CAD & G-CSF

CAD: Cyclophosphamide, Adriamycin (Doxorubicin), Dexamethasone

Regimen

Study	Dates of enrollment	Evidence
Lokhorst et al. 2009 (HOVON-50)	2001-2005	Non-randomized part of phase 3 RCT

This is reported as a stem cell mobilization regimen but presumably has anti-myeloma activity.

Preceding treatment

TAD versus VAD induction

Chemotherapy

Cyclophosphamide (Cytoxan) 1000 mg/m² IV once on day 1
Doxorubicin (Adriamycin) 15 mg/m² IV once per day on days 1 to 4

Glucocorticoid therapy

Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4

Growth factor therapy

Filgrastim (Neupogen) 5 mcg/kg SC twice per day until collection completed

One course

Subsequent treatment

High-dose melphalan, then auto HSCT or tandem high-dose melphalan, then auto HSCT consolidation (this was not a randomization but was pre-determined by the treating center)

References

HOVON-50: Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010 Feb 11;115(6):1113-20. Epub 2009 Oct 30. link to original article contains dosing details in manuscript PubMed NCT00028886
1. Update: van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematol. 2018 Oct;5(10):e479-e492. link to original article PubMed

Cyclophosphamide & G-CSF

Regimen variant #1

Study	Dates of enrollment	Evidence
Oakervee et al. 2005	NR	Phase 2

Chemotherapy

Cyclophosphamide (Cytoxan) 1500 mg/m² IV once on day 1

Growth factor therapy

Lenograstim (Granocyte) 263 mcg SC once per day, starting on day 4

Stem cell collection begins on day 10 and continues until at least 2 × 10⁶ CD34+ cells/kg are collected.

Regimen variant #2

Study	Dates of enrollment	Evidence
Royer et al. 2016	2010-04 to 2013-07	Phase 2

Chemotherapy

Cyclophosphamide (Cytoxan) 3000 mg/m² IV once

Growth factor therapy

Filgrastim (Neupogen) 10 mcg/kg SC once per day and continued until at least 4 × 10⁶ CD34+ cells/kg are collected

One course

References

Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. link to original article contains dosing details in manuscript PubMed
Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP; Intergroupe Francophone du Myélome. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. link to original article contains dosing details in abstract PubMed EudraCT 2009-016607-33

Cytarabine & G-CSF

Regimen variant #1, 2000 mg/m² x 8

Study	Evidence
Yanada et al. 2013 (JALSG APL205R)	Phase 2

Note: Target CD34+ cell dose: 2 × 10⁶/kg

Chemotherapy

Cytarabine (Ara-C) 2000 mg/m² IV over 3 hours twice per day on days 1 to 4 (total dose: 16,000 mg/m²)

Growth factor therapy

Filgrastim (Neupogen) starting on day 6 (dose, frequency not specified)

One course

Regimen variant #2, 3000 mg/m² x 2

Study	Dates of enrollment	Evidence
Abrey et al. 2003	NR	Phase 2

Chemotherapy

Cytarabine (Ara-C) 3000 mg/m² IV once per day on days 1 & 2

Growth factor therapy

Filgrastim (Neupogen) 10 mcg/kg SC once per day, starting on day 4 and continued until stem cell collection complete

One course

References

Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6. link to original article contains dosing details in manuscript PubMed
JALSG APL205R: Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N; Japan Adult Leukemia Study Group. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 Apr 18;121(16):3095-102. Epub 2013 Feb 14. link to original article contains dosing details in manuscript PubMed NCT01908621
MMMobil-COI-01: Czerw T, Sadus-Wojciechowska M, Michalak K, Najda J, Mendrek W, Sobczyk-Kruszelnicka M, Glowala-Kosinska M, Chwieduk A, Mitrus I, Smagur A, Holowiecki J, Giebel S. Increased Efficacy of Stem Cell Chemomobilization with Intermediate-Dose Cytarabine Plus Granulocyte Colony-Stimulating Factor (G-CSF) Compared with G-CSF Alone in Patients with Multiple Myeloma: Results of a Randomized Trial. Biol Blood Marrow Transplant. 2019 Feb;25(2):248-255. Epub 2018 Sep 26. link to original article PubMed NCT01908621

Cytarabine, Ifosfamide, G-CSF

Regimen

Study	Dates of enrollment	Evidence
Colombat et al. 2006	1999-2001	Phase 2

Chemotherapy

Cytarabine (Ara-C) 1000 mg/m² IV every 12 hours on days 1 & 2
Ifosfamide (Ifex) 1500 mg/m² IV once per day on days 1 to 3

Growth factor therapy

Filgrastim (Neupogen) (dose/frequency not specified)

One course

References

Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. link to original article contains dosing details in manuscript PubMed

Cytarabine & Etoposide (CYVE) & G-CSF

CYVE & G-CSF: CYtarabine, VEpesid (Etoposide), Granulocyte Colony Stimulating Factor

Regimen

Study	Dates of enrollment	Evidence
Soussain et al. 2001	1992-03 to 1995-03	Pilot, >20 pts
Soussain et al. 2008	2000-01 to 2005-12	Phase 2

Note: Target collection dose not described; mobilization took place after the first course of CYVE salvage for CNS lymphoma.

Chemotherapy

Cytarabine (Ara-C) 2000 mg/m² IV over 3 hours once per day on days 2 to 5
Cytarabine (Ara-C) 50 mg/m² IV over 12 hours once per day on days 1 to 5
Etoposide (Vepesid) 200 mg/m² IV over 2 hours once per day on days 2 to 5

Growth factor therapy

Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting 48 hours after end of chemotherapy

One course

References

Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001 Feb 1;19(3):742-9. link to original article contains dosing details in manuscript PubMed
Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. Epub 2008 Apr 14. link to original article contains dosing details in manuscript PubMed

DCEP & G-CSF

DCEP & G-CSF: Dexamethasone, Cyclophosphamide, Etoposide, Platinol (Cisplatin), Granulocyte Colony Stimulating Factor

Regimen

Study	Dates of enrollment	Evidence
Corso et al. 2004	1996-2002	Phase 2

Note: Stem cells are mobilized and collected after each course of therapy.

Glucocorticoid therapy

Dexamethasone (Decadron) 40 mg PO once per day on days 1 to 4

Chemotherapy

Cyclophosphamide (Cytoxan) 400 mg/m²/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 1600 mg/m²)
Etoposide (Vepesid) 40 mg/m²/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 160 mg/m²)
Cisplatin (Platinol) 10 mg/m²/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m²)

Supportive therapy

Filgrastim (Neupogen) 5 mcg/kg SC once per day, starting 48 hours after chemotherapy and continuing through stem cell collection

2 cycles (length not specified)

References

Corso A, Barbarano L, Zappasodi P, Cairoli R, Alessandrino EP, Mangiacavalli S, Ferrari D, Fava S, Fiumanò M, Frigerio G, Isa L, Luraschi A, Klersy C, De Paoli A, Vergani C, Banfi L, Perego D, Ucci G, Pinotti G, Savarè M, Uziel L, Vismara A, Morra E, Lazzarino M. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma. Haematologica. 2004 Sep;89(9):1124-7. link to original article contains dosing details in manuscript PubMed

EAR & G-CSF

EAR & G-CSF: Etoposide, Ara-C (Cytarabine), Rituximab, Granulocyte Colony Stimulating Factor

Regimen

Study	Dates of enrollment	Evidence
Damon et al. 2009 (CALGB 59909)	2001-2004	Phase 2

Note: Text specified that PJP prophylaxis started during mobilization --although table 1 did not list it-- to continue until 3 months after auto HSCT.

Preceding treatment

R-M-CHOP induction x 2 to 3 cycles

Chemotherapy

Etoposide (Vepesid) 10 mg/kg/day IV continuous infusion over 96 hours, started on day 1 (total dose: 40 mg/kg)
Cytarabine (Ara-C) 2000 mg/m² IV over 2 hours twice per day on days 1 to 4 (total dose: 16,000 mg/m²)

Targeted therapy

Rituximab (Rituxan) 375 mg/m² IV once per day on days 6 & 13

Supportive therapy

Filgrastim (Neupogen) 10 mcg/kg SC once per day, starting on day 14, to continue until peripheral blood stem cell collection is complete
Levofloxacin (Levaquin) 500 mg PO once per day, starting on day 7, to continue until ANC greater than or equal to 500/μL
Fluconazole (Diflucan) 200 mg PO once per day, starting on day 6, to continue until ANC greater than or equal to 500/μL
Acyclovir (Zovirax) 200 mg PO three times per day, starting on day 6, to continue until 1 year after auto HSCT
Trimethoprim-Sulfamethoxazole (Bactrim DS) prophylaxis

Daily leukapheresis to start when WBC count more than or equal to 5 x 10⁹/L One course

Subsequent treatment

CALGB 59909, patients with adequate collection and meeting criteria: CBV with autologous HSCT consolidation

References

CALGB 59909: Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20;27(36):6101-8. Epub 2009 Nov 16. link to original article contains dosing details in abstract link to PMC article PubMed

IGEV & G-CSF

IGEV & G-CSF: Ifosfamide, GEmcitabine, Vinorelbine, Granulocyte Colony Stimulating Factor

Regimen

Study	Dates of enrollment	Evidence
Magagnoli et al. 2007	1997-11 to 2006-07	Phase 2

Chemotherapy

Ifosfamide (Ifex) 2000 mg/m² IV over 2 hours once per day on days 1 to 4
Gemcitabine (Gemzar) 800 mg/m² IV once per day on days 1 & 4
Vinorelbine (Navelbine) 20 mg/m² IV once on day 1

Glucocorticoid therapy

Prednisolone (Millipred) 100 mg PO once per day on days 1 to 4

Supportive therapy

Mesna (Mesnex) 900 mg/m² IV three times per day on days 1 to 4, given at 0, 2, 4 hours after ifosfamide (total dose: 10,800 mg/m²)
Lenograstim (Granocyte) 263 mcg SC once per day on days 7 until at least 3 x 10⁶ CD34+ cells per kg of body weight were collected

Apheresis was performed when the peripheral blood CD34+ cell count exceeded 10 cells/ul. One course

References

Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant. 2007 Dec;40(11):1019-25. Epub 2007 Oct 1. link to original article contains dosing details in manuscript PubMed

DexaBEAM & G-CSF

DexaBEAM & G-CSF: Dexamethasone, BiCNU (Carmustine), Etoposide, Ara-C (Cytarabine), Melphalan, Granulocyte Colony Stimulating Factor

Regimen

Study	Dates of enrollment	Evidence
Dreyling et al. 2004	1996-2004	Non-randomized part of phase 3 RCT

Glucocorticoid therapy

Dexamethasone (Decadron) 8 mg PO three times per day on days 1 to 10

Chemotherapy

Carmustine (BCNU) 60 mg/m² IV once on day 2
Etoposide (Vepesid) 75 mg/m² IV once per day on days 4 to 7
Cytarabine (Ara-C) 100 mg/m² IV twice per day on days 4 to 7
Melphalan (Alkeran) 20 mg/m² IV once on day 3

Growth factor therapy

G-CSF starting on day 11

A minimum of 1 × 10⁶ CD34+ cells/kg are collected. One course

References

Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. link to original article contains dosing details in manuscript PubMed

Motixafortide & G-CSF

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Crees et al. 2023 (GENESIS)	2018-01-22 to 2020-10-30	Phase 3 (E-RT-esc)	G-CSF	Superior primary endpoint

Growth factor therapy

One course

References

GENESIS: Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, Pereira D, Micallef I, Moreno-Jiménez G, Mikala G, Coronel MLP, Holtick U, Hiemenz J, Qazilbash MH, Hardy N, Latif T, García-Cadenas I, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Goldstein I, Ickowicz D, Shemesh-Darvish L, Kadosh S, Gao F, Schroeder MA, Vij R, DiPersio JF. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023 Apr;29(4):869-879. Epub 2023 Apr 17. link to original article link to PMC article PubMed NCT03246529

Plerixafor & G-CSF

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
DiPersio et al. 2009 (Study 3101)	2005-01-18 to 2006-08-20	Phase 3 (E-esc)	G-CSF	Superior primary endpoint
DiPersio et al. 2009 (AMD3100-3102)	2005-02-04 to 2006-07-07	Phase 3 (E-esc)	G-CSF	Superior primary endpoint

Growth factor therapy

One course

References

AMD3100-3102: DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf S, Horwitz M, Cooper D, Bridger G, Calandra G; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009 Jun 4;113(23):5720-6. Epub 2009 Apr 10. link to original article PubMed NCT00103662
Study 3101: DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009 Oct 1;27(28):4767-73. Epub 2009 Aug 31. link to original article PubMed NCT00103610

@@ Line 3: / Line 3: @@
 [[#top|Back to Top]]
 </div>
-{| class="wikitable" style="text-align:center; width:50%;"
+{{#lst:Editorial board transclusions|transplant}}
-!colspan="2" align="center" style="color:white; font-size:125%; background-color:#4a1486"|'''Section editor'''
+Unlike the other chemotherapy regimen pages, this one is not disease-specific. Rather, this is meant to be a gathering point for all stem cell mobilization regimens.
-|-
-|style="background-color:#F0F0F0"|[[File:Hilal.jpg|frameless|upright=0.3|center]]
-|<big>Talal Hilal, MD<br>University of Mississippi<br>Jackson, MS</big><br>[[File:Social-twitter-icon.png|frameless|upright=0.1]] [https://twitter.com/THilalMD THilalMD]
-|-
-|}
-Unlike the other chemotherapy regimen pages, this one is not disease-specific. Rather, this is meant to be a gathering point for all stem cell mobilization  regimens.
 {| class="wikitable" style="float:right; margin-right: 5px;"
 |-
@@ Line 18: / Line 11: @@
 |}
 {{TOC limit|limit=3}}
 =Stem cell mobilization, all lines of therapy=
 ''These are regimens intended to mobilize stem cells, very incomplete right now but will be filled in over time.''
 ==CAD & G-CSF {{#subobject:b3c37f|Regimen=1}}==
 CAD: '''<u>C</u>'''yclophosphamide, '''<u>A</u>'''driamycin (Doxorubicin), '''<u>D</u>'''examethasone
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:0e8781|Variant=1}}===
-{| class="wikitable" style="width: 40%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 25%"|Study
+!style="width: 33%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[http://www.bloodjournal.org/content/115/6/1113 Lokhorst et al. 2009 (HOVON-50)]
-|style="background-color:#91cf61"|Non-randomized portion of RCT
+|2001-2005
+|style="background-color:#91cf61"|Non-randomized part of phase 3 RCT
 |-
 |}
 ''This is reported as a stem cell mobilization regimen but presumably has anti-myeloma activity.''
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
 *[[Multiple_myeloma,_induction#TAD_.28Thalidomide.29|TAD]] versus [[Multiple_myeloma_-_historical#VAD|VAD]] induction
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cyclophosphamide (Cytoxan)]] 1000 mg/m<sup>2</sup> IV once on day 1
@@ Line 45: / Line 40: @@
 ====Growth factor therapy====
 *[[Filgrastim (Neupogen)]] 5 mcg/kg SC twice per day until collection completed
 '''One course'''
+</div>
+<div class="toccolours" style="background-color:#cbd5e7">
 ====Subsequent treatment====
-*[[Multiple_myeloma,_consolidation_and_maintenance#Melphalan.2C_then_auto_HSCT|High-dose melphalan, then auto HSCT]] or [[Multiple_myeloma,_consolidation_and_maintenance#Tandem_melphalan.2C_then_auto_HSCT|tandem high-dose melphalan, then auto HSCT]] (this was not a randomization but was pre-determined by the treating center)
+*[[Multiple_myeloma,_consolidation_and_maintenance#Melphalan_monotherapy.2C_then_auto_HSCT|High-dose melphalan, then auto HSCT]] or [[Multiple_myeloma,_consolidation_and_maintenance#Tandem_melphalan.2C_then_auto_HSCT|tandem high-dose melphalan, then auto HSCT]] consolidation (this was not a randomization but was pre-determined by the treating center)
+</div></div>
 ===References===
-<!-- Presented in part at the 50th Annual Meeting of the American Society of Hematology, San Francisco, CA, December 7, 2008. -->
+# '''HOVON-50:''' Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010 Feb 11;115(6):1113-20. Epub 2009 Oct 30. [http://www.bloodjournal.org/content/115/6/1113 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19880501/ PubMed] [https://clinicaltrials.gov/study/NCT00028886 NCT00028886]
-# '''HOVON-50:''' Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S, van Oers MH, von dem Borne P, Wijermans P, Schaafsma R, de Weerdt O, Wittebol S, Delforge M, Berenschot H, Bos GM, Jie KS, Sinnige H, van Marwijk-Kooy M, Joosten P, Minnema MC, van Ammerlaan R, Sonneveld P; Dutch-Belgian Hemato-Oncology Group (HOVON). A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010 Feb 11;115(6):1113-20. Epub 2009 Oct 30. [http://www.bloodjournal.org/content/115/6/1113 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/19880501 PubMed] NCT00028886
+## '''Update:''' van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematol. 2018 Oct;5(10):e479-e492. [https://doi.org/10.1016/S2352-3026(18)30149-2 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30290905/ PubMed]
-## '''Update:''' van de Donk NW, van der Holt B, Minnema MC, Vellenga E, Croockewit S, Kersten MJ, von dem Borne PA, Ypma P, Schaafsma R, de Weerdt O, Klein SK, Delforge M, Levin MD, Bos GM, Jie KG, Sinnige H, Coenen JL, de Waal EG, Zweegman S, Sonneveld P, Lokhorst HM. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. Lancet Haematol. 2018 Oct;5(10):e479-e492. [https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(18)30149-2/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/30290905 PubMed]
 ==Cyclophosphamide & G-CSF {{#subobject:ebc1f1|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1 {{#subobject:f033a9|Variant=1}}===
-{| class="wikitable" style="width: 40%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 25%"|Study
+!style="width: 33%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
-|[https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2005.05519.x/full Oakervee et al. 2005]
+|[https://doi.org/10.1111/j.1365-2141.2005.05519.x Oakervee et al. 2005]
+|NR
 |style="background-color:#91cf61"|Phase 2
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cyclophosphamide (Cytoxan)]] 1500 mg/m<sup>2</sup> IV once on day 1
 ====Growth factor therapy====
 *[[Lenograstim (Granocyte)]] 263 mcg SC once per day, starting on day 4
 '''Stem cell collection begins on day 10 and continues until at least 2 × 10<sup>6</sup> CD34+ cells/kg are collected.'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2 {{#subobject:0aa051|Variant=1}}===
-{| class="wikitable" style="width: 40%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 25%"|Study
+!style="width: 33%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://doi.org/10.1200/jco.2015.63.1929 Royer et al. 2016]
+|2010-04 to 2013-07
 |style="background-color:#91cf61"|Phase 2
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cyclophosphamide (Cytoxan)]] 3000 mg/m<sup>2</sup> IV once
 ====Growth factor therapy====
 *[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day and continued until at least 4 × 10<sup>6</sup> CD34+ cells/kg are collected
+'''One course'''
+</div></div>
 ===References===
-# Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. [https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2005.05519.x/full link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15953001 PubMed]
+# Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, Agrawal S, Stec J, Schenkein D, Esseltine DL, Cavenagh JD. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005 Jun;129(6):755-62. [https://doi.org/10.1111/j.1365-2141.2005.05519.x link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15953001/ PubMed]
-<!-- Presented at the 55th American Society of Hematology Annual Meeting, New Orleans, LA, December 7-10, 2013, and the 40th Annual Meeting of the European Society for Blood and Marrow Transplantation, Milan, Italy, March 30 to April 2, 2014. -->
+# Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP; Intergroupe Francophone du Myélome. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. [https://doi.org/10.1200/jco.2015.63.1929 link to original article] '''contains dosing details in abstract''' [https://pubmed.ncbi.nlm.nih.gov/27114594/ PubMed] EudraCT 2009-016607-33
-# Royer B, Minvielle S, Diouf M, Roussel M, Karlin L, Hulin C, Arnulf B, Macro M, Cailleres S, Brion A, Brechignac S, Belhadj K, Chretien ML, Wetterwald M, Chaleteix C, Tiab M, Leleu X, Frenzel L, Garderet L, Choquet S, Fuzibet JG, Dauriac C, Forneker LM, Benboubker L, Facon T, Moreau P, Avet-Loiseau H, Marolleau JP; Intergroupe Francophone du Myélome. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol. 2016 Jun 20;34(18):2125-32. Epub 2016 Apr 25. [https://doi.org/10.1200/jco.2015.63.1929 link to original article] '''contains protocol''' [https://pubmed.ncbi.nlm.nih.gov/27114594 PubMed] EudraCT 2009-016607-33
 ==Cytarabine & G-CSF {{#subobject:ec0d95|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #1, 2000 mg/m<sup>2</sup> x 8 {{#subobject:36556f|Variant=1}}===
 {| class="wikitable" style="width: 40%; text-align:center;"
 !style="width: 25%"|Study
 !style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
@@ Line 103: / Line 103: @@
 |-
 |}
-''Target CD34+ cell dose: 2 × 10<sup>6</sup>/kg''
+''Note: Target CD34+ cell dose: 2 × 10<sup>6</sup>/kg''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cytarabine (Ara-C)]] 2000 mg/m<sup>2</sup> IV over 3 hours twice per day on days 1 to 4 (total dose: 16,000 mg/m<sup>2</sup>)
 ====Growth factor therapy====
 *[[Filgrastim (Neupogen)]] starting on day 6 (dose, frequency not specified)
+'''One course'''
+</div></div><br>
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen variant #2, 3000 mg/m<sup>2</sup> x 2 {{#subobject:08473f|Variant=1}}===
-{| class="wikitable" style="width: 40%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 25%"|Study
+!style="width: 33%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://doi.org/10.1200/jco.2003.05.024 Abrey et al. 2003]
+|NR
 |style="background-color:#91cf61"|Phase 2
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cytarabine (Ara-C)]] 3000 mg/m<sup>2</sup> IV once per day on days 1 & 2
 ====Growth factor therapy====
 *[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day, starting on day 4 and continued until stem cell collection complete
+'''One course'''
+</div></div>
 ===References===
-# Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6. [https://doi.org/10.1200/jco.2003.05.024 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/14615443 PubMed]
+# Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6. [https://doi.org/10.1200/jco.2003.05.024 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/14615443/ PubMed]
-# '''JALSG APL205R:''' Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N; Japan Adult Leukemia Study Group. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 Apr 18;121(16):3095-102. Epub 2013 Feb 14. [http://www.bloodjournal.org/content/121/16/3095.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23412094 PubMed] UMIN C000000302
+# '''JALSG APL205R:''' Yanada M, Tsuzuki M, Fujita H, Fujimaki K, Fujisawa S, Sunami K, Taniwaki M, Ohwada A, Tsuboi K, Maeda A, Takeshita A, Ohtake S, Miyazaki Y, Atsuta Y, Kobayashi Y, Naoe T, Emi N; Japan Adult Leukemia Study Group. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 Apr 18;121(16):3095-102. Epub 2013 Feb 14. [http://www.bloodjournal.org/content/121/16/3095.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/23412094/ PubMed] [https://clinicaltrials.gov/study/NCT01908621 NCT01908621]
-# '''MMMobil-COI-01:''' Czerw T, Sadus-Wojciechowska M, Michalak K, Najda J, Mendrek W, Sobczyk-Kruszelnicka M, Glowala-Kosinska M, Chwieduk A, Mitrus I, Smagur A, Holowiecki J, Giebel S. Increased Efficacy of Stem Cell Chemomobilization with Intermediate-Dose Cytarabine Plus Granulocyte Colony-Stimulating Factor (G-CSF) Compared with G-CSF Alone in Patients with Multiple Myeloma: Results of a Randomized Trial. Biol Blood Marrow Transplant. 2019 Feb;25(2):248-255. Epub 2018 Sep 26. [https://www.bbmt.org/article/S1083-8791(18)30590-1/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/30266677 PubMed] NCT01908621
+# '''MMMobil-COI-01:''' Czerw T, Sadus-Wojciechowska M, Michalak K, Najda J, Mendrek W, Sobczyk-Kruszelnicka M, Glowala-Kosinska M, Chwieduk A, Mitrus I, Smagur A, Holowiecki J, Giebel S. Increased Efficacy of Stem Cell Chemomobilization with Intermediate-Dose Cytarabine Plus Granulocyte Colony-Stimulating Factor (G-CSF) Compared with G-CSF Alone in Patients with Multiple Myeloma: Results of a Randomized Trial. Biol Blood Marrow Transplant. 2019 Feb;25(2):248-255. Epub 2018 Sep 26. [https://www.bbmt.org/article/S1083-8791(18)30590-1 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30266677/ PubMed] [https://clinicaltrials.gov/study/NCT01908621 NCT01908621]
 ==Cytarabine, Ifosfamide, G-CSF {{#subobject:32fc16|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:a8f29e|Variant=1}}===
-{| class="wikitable" style="width: 40%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 25%"|Study
+!style="width: 33%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://doi.org/10.1038/sj.bmt.1705452 Colombat et al. 2006]
+|1999-2001
 |style="background-color:#91cf61"|Phase 2
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Cytarabine (Ara-C)]] 1000 mg/m<sup>2</sup> IV every 12 hours on days 1 & 2
@@ Line 146: / Line 154: @@
 ====Growth factor therapy====
 *[[Filgrastim (Neupogen)]] (dose/frequency not specified)
+'''One course'''
+</div></div>
 ===References===
-# Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. [https://doi.org/10.1038/sj.bmt.1705452 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16951691 PubMed]
+# Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20. [https://doi.org/10.1038/sj.bmt.1705452 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/16951691/ PubMed]
-==CYVE & G-CSF {{#subobject:a2d919|Regimen=1}}==
+==Cytarabine & Etoposide (CYVE) & G-CSF {{#subobject:a2d919|Regimen=1}}==
 CYVE & G-CSF: '''<u>CY</u>'''tarabine, '''<u>VE</u>'''pesid (Etoposide), '''<u>G</u>'''ranulocyte '''<u>C</u>'''olony '''<u>S</u>'''timulating '''<u>F</u>'''actor
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:b4b13a|Variant=1}}===
-{| class="wikitable" style="width: 40%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 25%"|Study
+!style="width: 33%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://doi.org/10.1200/jco.2001.19.3.742 Soussain et al. 2001]
+|1992-03 to 1995-03
 |style="background-color:#91cf61"|Pilot, >20 pts
 |-
 |[https://doi.org/10.1200/jco.2007.13.5533 Soussain et al. 2008]
+|2000-01 to 2005-12
 |style="background-color:#91cf61"|Phase 2
 |-
 |}
-''Target collection dose not described; mobilization took place after the first course of [[CNS_lymphoma#CYVE|CYVE salvage for CNS lymphoma]].''
+''Note: Target collection dose not described; mobilization took place after the first course of [[CNS_lymphoma#Cytarabine_.26_Etoposide_.28CYVE.29|CYVE salvage for CNS lymphoma]].''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
-*[[Cytarabine (Ara-C)]] by the following split schedule:
+*[[Cytarabine (Ara-C)]] 2000 mg/m<sup>2</sup> IV over 3 hours once per day on days 2 to 5
-**2000 mg/m<sup>2</sup> IV over 3 hours once per day on days 2 to 5
+*[[Cytarabine (Ara-C)]] 50 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5
-**50 mg/m<sup>2</sup> IV over 12 hours once per day on days 1 to 5
 *[[Etoposide (Vepesid)]] 200 mg/m<sup>2</sup> IV over 2 hours once per day on days 2 to 5
 ====Growth factor therapy====
 *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting 48 hours after end of chemotherapy
+'''One course'''
+</div></div>
 ===References===
-# Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001 Feb 1;19(3):742-9. [https://doi.org/10.1200/jco.2001.19.3.742 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11157026 PubMed]
+# Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol. 2001 Feb 1;19(3):742-9. [https://doi.org/10.1200/jco.2001.19.3.742 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/11157026/ PubMed]
-# Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. Epub 2008 Apr 14. [https://doi.org/10.1200/jco.2007.13.5533 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18413641 PubMed]
+# Soussain C, Hoang-Xuan K, Taillandier L, Fourme E, Choquet S, Witz F, Casasnovas O, Dupriez B, Souleau B, Taksin AL, Gisselbrecht C, Jaccard A, Omuro A, Sanson M, Janvier M, Kolb B, Zini JM, Leblond V; Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire. J Clin Oncol. 2008 May 20;26(15):2512-8. Epub 2008 Apr 14. [https://doi.org/10.1200/jco.2007.13.5533 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/18413641/ PubMed]
 ==DCEP & G-CSF {{#subobject:6e3266|Regimen=1}}==
 DCEP & G-CSF: '''<u>D</u>'''examethasone, '''<u>C</u>'''yclophosphamide, '''<u>E</u>'''toposide, '''<u>P</u>'''latinol (Cisplatin), '''<u>G</u>'''ranulocyte '''<u>C</u>'''olony '''<u>S</u>'''timulating '''<u>F</u>'''actor
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:8d0e51|Variant=1}}===
-{| class="wikitable" style="width: 40%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 25%"|Study
+!style="width: 33%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[http://www.haematologica.org/content/89/9/1124.long Corso et al. 2004]
+|1996-2002
 |style="background-color:#91cf61"|Phase 2
 |-
 |}
-''Stem cells are mobilized and collected after each course of therapy.''
+''Note: Stem cells are mobilized and collected after each course of therapy.''
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Glucocorticoid therapy====
 *[[Dexamethasone (Decadron)]] 40 mg PO once per day on days 1 to 4
@@ Line 198: / Line 212: @@
 *[[Etoposide (Vepesid)]] 40 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 160 mg/m<sup>2</sup>)
 *[[Cisplatin (Platinol)]] 10 mg/m<sup>2</sup>/day IV continuous infusion over 96 hours, started on day 1 (total dose per cycle: 40 mg/m<sup>2</sup>)
+====Supportive therapy====
-====Supportive medications====
 *[[Filgrastim (Neupogen)]] 5 mcg/kg SC once per day, starting 48 hours after chemotherapy and continuing through stem cell collection
 '''2 cycles (length not specified)'''
+</div></div>
 ===References===
-# Corso A, Barbarano L, Zappasodi P, Cairoli R, Alessandrino EP, Mangiacavalli S, Ferrari D, Fava S, Fiumanò M, Frigerio G, Isa L, Luraschi A, Klersy C, De Paoli A, Vergani C, Banfi L, Perego D, Ucci G, Pinotti G, Savarè M, Uziel L, Vismara A, Morra E, Lazzarino M. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma. Haematologica. 2004 Sep;89(9):1124-7. [http://www.haematologica.org/content/89/9/1124.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15377474 PubMed]
+# Corso A, Barbarano L, Zappasodi P, Cairoli R, Alessandrino EP, Mangiacavalli S, Ferrari D, Fava S, Fiumanò M, Frigerio G, Isa L, Luraschi A, Klersy C, De Paoli A, Vergani C, Banfi L, Perego D, Ucci G, Pinotti G, Savarè M, Uziel L, Vismara A, Morra E, Lazzarino M. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma. Haematologica. 2004 Sep;89(9):1124-7. [http://www.haematologica.org/content/89/9/1124.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15377474/ PubMed]
 ==EAR & G-CSF {{#subobject:358013|Regimen=1}}==
 EAR & G-CSF: '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>R</u>'''ituximab, '''<u>G</u>'''ranulocyte '''<u>C</u>'''olony '''<u>S</u>'''timulating '''<u>F</u>'''actor
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:e580e|Variant=1}}===
-{| class="wikitable" style="width: 40%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 25%"|Study
+!style="width: 33%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793032/ Damon et al. 2009 (CALGB 59909)]
+|2001-2004
 |style="background-color:#91cf61"|Phase 2
 |-
 |}
 ''Note: Text specified that PJP prophylaxis started during mobilization --although table 1 did not list it-- to continue until 3 months after auto HSCT.''
+<div class="toccolours" style="background-color:#cbd5e8">
 ====Preceding treatment====
-*[[Mantle_cell_lymphoma#R-M-CHOP|R-M-CHOP]] x 2 to 3 cycles
+*[[Mantle_cell_lymphoma#R-M-CHOP|R-M-CHOP]] induction x 2 to 3 cycles
+</div>
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Etoposide (Vepesid)]] 10 mg/kg/day IV continuous infusion over 96 hours, started on day 1 (total dose: 40 mg/kg)
@@ Line 228: / Line 243: @@
 ====Targeted therapy====
 *[[Rituximab (Rituxan)]] 375 mg/m<sup>2</sup> IV once per day on days 6 & 13
+====Supportive therapy====
-====Supportive medications====
 *[[Filgrastim (Neupogen)]] 10 mcg/kg SC once per day, starting on day 14, to continue until peripheral blood stem cell collection is complete
-*[[Levofloxacin (Levaquin)]] 500 mg PO once per day, starting on day 7, to continue until ANC greater than or equal to 500/uL
+*[[Levofloxacin (Levaquin)]] 500 mg PO once per day, starting on day 7, to continue until ANC greater than or equal to 500/μL
-*[[Fluconazole (Diflucan)]] 200 mg PO once per day, starting on day 6, to continue until ANC greater than or equal to 500/uL
+*[[Fluconazole (Diflucan)]] 200 mg PO once per day, starting on day 6, to continue until ANC greater than or equal to 500/μL
 *[[Acyclovir (Zovirax)]] 200 mg PO three times per day, starting on day 6, to continue until 1 year after auto HSCT
 *[[Trimethoprim-Sulfamethoxazole (Bactrim DS)]] prophylaxis
+'''Daily leukapheresis to start when WBC count more than or equal to 5 x 10<sup>9</sup>/L'''
-'''Daily leukapheresis to start when WBC count greater than or equal to 5 x 10<sup>9</sup>/L'''
+'''One course'''
+</div>
+<div class="toccolours" style="background-color:#cbd5e7">
 ====Subsequent treatment====
-*Patients with adequate collection and meeting criteria: [[Mantle_cell_lymphoma#CBV.2C_then_auto_HSCT|CBV with autologous HSCT]]
+*CALGB 59909, patients with adequate collection and meeting criteria: [[Mantle_cell_lymphoma#CBV.2C_then_auto_HSCT|CBV with autologous HSCT]] consolidation
+</div></div>
 ===References===
-# '''CALGB 59909:''' Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20;27(36):6101-8. Epub 2009 Nov 16. [https://doi.org/10.1200/jco.2009.22.2554 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793032/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19917845 PubMed]
+# '''CALGB 59909:''' Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol. 2009 Dec 20;27(36):6101-8. Epub 2009 Nov 16. [https://doi.org/10.1200/jco.2009.22.2554 link to original article] '''contains dosing details in abstract''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2793032/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/19917845/ PubMed]
 ==IGEV & G-CSF {{#subobject:b15f5c|Regimen=1}}==
 IGEV & G-CSF: '''<u>I</u>'''fosfamide, '''<u>GE</u>'''mcitabine, '''<u>V</u>'''inorelbine, '''<u>G</u>'''ranulocyte '''<u>C</u>'''olony '''<u>S</u>'''timulating '''<u>F</u>'''actor
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:116473|Variant=1}}===
-{| class="wikitable" style="width: 40%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 25%"|Study
+!style="width: 33%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[https://doi.org/10.1038/sj.bmt.1705862 Magagnoli et al. 2007]
+|1997-11 to 2006-07
 |style="background-color:#91cf61"|Phase 2
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Chemotherapy====
 *[[Ifosfamide (Ifex)]] 2000 mg/m<sup>2</sup> IV over 2 hours once per day on days 1 to 4
 *[[Gemcitabine (Gemzar)]] 800 mg/m<sup>2</sup> IV once per day on days 1 & 4
 *[[Vinorelbine (Navelbine)]] 20 mg/m<sup>2</sup> IV once on day 1
-====Corticosteroid therapy====
+====Glucocorticoid therapy====
 *[[Prednisolone (Millipred)]] 100 mg PO once per day on days 1 to 4
+====Supportive therapy====
-====Supportive medications====
+*[[Mesna (Mesnex)]] 900 mg/m<sup>2</sup> IV three times per day on days 1 to 4, '''given at 0, 2, 4 hours after ifosfamide''' (total dose: 10,800 mg/m<sup>2</sup>)
-*[[Mesna (Mesnex)]] 900 mg/m<sup>2</sup> IV three times per day on days 1 to 4, '''given at 0, 2, 4 hours after [[Ifosfamide (Ifex)]]''' (total dose: 10,800 mg/m<sup>2</sup>)
 *[[Lenograstim (Granocyte)]] 263 mcg SC once per day on days 7 until at least 3 x 10<sup>6</sup> CD34+ cells per kg of body weight were collected
 '''Apheresis was performed when the peripheral blood CD34+ cell count exceeded 10 cells/ul.'''
+'''One course'''
+</div></div>
 ===References===
-# Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant. 2007 Dec;40(11):1019-25. Epub 2007 Oct 1. [https://doi.org/10.1038/sj.bmt.1705862 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17906705 PubMed]
+# Magagnoli M, Spina M, Balzarotti M, Timofeeva I, Isa L, Michieli M, Capizzuto R, Morenghi E, Castagna L, Tirelli U, Santoro A. IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplant. 2007 Dec;40(11):1019-25. Epub 2007 Oct 1. [https://doi.org/10.1038/sj.bmt.1705862 link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/17906705/ PubMed]
 ==DexaBEAM & G-CSF {{#subobject:542726|Regimen=1}}==
 DexaBEAM & G-CSF: '''<u>Dexa</u>'''methasone, '''<u>B</u>'''iCNU (Carmustine), '''<u>E</u>'''toposide, '''<u>A</u>'''ra-C (Cytarabine), '''<u>M</u>'''elphalan, '''<u>G</u>'''ranulocyte '''<u>C</u>'''olony '''<u>S</u>'''timulating '''<u>F</u>'''actor
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:41ae94|Variant=1}}===
-{| class="wikitable" style="width: 40%; text-align:center;"
+{| class="wikitable sortable" style="width: 60%; text-align:center;"
-!style="width: 25%"|Study
+!style="width: 33%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 33%"|Dates of enrollment
+!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
 |-
 |[http://www.bloodjournal.org/content/105/7/2677.long Dreyling et al. 2004]
-| style="background-color:#91cf61" |Non-randomized portion of RCT
+|1996-2004
+| style="background-color:#91cf61" |Non-randomized part of phase 3 RCT
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Glucocorticoid therapy====
 *[[Dexamethasone (Decadron)]] 8 mg PO three times per day on days 1 to 10
@@ Line 290: / Line 309: @@
 *[[Cytarabine (Ara-C)]] 100 mg/m<sup>2</sup> IV twice per day on days 4 to 7
 *[[Melphalan (Alkeran)]] 20 mg/m<sup>2</sup> IV once on day 3
 ====Growth factor therapy====
 *[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]] starting on day 11
 ''A minimum of 1 × 10<sup>6</sup> CD34+ cells/kg are collected.''
+'''One course'''
+</div></div>
+===References===
+# Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. [http://www.bloodjournal.org/content/105/7/2677.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15591112/ PubMed]
+==Motixafortide & G-CSF {{#subobject:87ojnc|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
+===Regimen {{#subobject:36uhcb|Variant=1}}===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Dates of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10115633/ Crees et al. 2023 (GENESIS)]
+|2018-01-22 to 2020-10-30
+| style="background-color:#1a9851" |Phase 3 (E-RT-esc)
+|[[#G-CSF_monotherapy|G-CSF]]
+| style="background-color:#1a9850" |Superior primary endpoint
+|-
+|}
+<div class="toccolours" style="background-color:#b3e2cd">
+====Growth factor therapy====
+*[[Motixafortide (Aphexda)]]
+*[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]]
+'''One course'''
+</div></div>
 ===References===
-# Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9. [http://www.bloodjournal.org/content/105/7/2677.long link to original article] '''contains dosing details in manuscript''' [https://pubmed.ncbi.nlm.nih.gov/15591112 PubMed]
+#'''GENESIS:''' Crees ZD, Rettig MP, Jayasinghe RG, Stockerl-Goldstein K, Larson SM, Arpad I, Milone GA, Martino M, Stiff P, Sborov D, Pereira D, Micallef I, Moreno-Jiménez G, Mikala G, Coronel MLP, Holtick U, Hiemenz J, Qazilbash MH, Hardy N, Latif T, García-Cadenas I, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Goldstein I, Ickowicz D, Shemesh-Darvish L, Kadosh S, Gao F, Schroeder MA, Vij R, DiPersio JF. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat Med. 2023 Apr;29(4):869-879. Epub 2023 Apr 17. [https://doi.org/10.1038/s41591-023-02273-z link to original article] [http://www.ncbi.nlm.nih.gov/pmc/articles/pmc10115633/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/37069359/ PubMed] [https://clinicaltrials.gov/study/NCT03246529 NCT03246529]
 ==Plerixafor & G-CSF {{#subobject:87yb26|Regimen=1}}==
+<div class="toccolours" style="background-color:#eeeeee">
 ===Regimen {{#subobject:36hz94|Variant=1}}===
 {| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 25%"|Study
+!style="width: 20%"|Study
-!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Dates of enrollment
-!style="width: 25%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 25%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
 |-
 |[https://doi.org/10.1200/JCO.2008.20.7209 DiPersio et al. 2009 (Study 3101)]
-| style="background-color:#1a9851" |Phase 3 (E-switch-ic)
+|2005-01-18 to 2006-08-20
-|G-CSF
+| style="background-color:#1a9851" |Phase 3 (E-esc)
+|[[#G-CSF_monotherapy|G-CSF]]
+| style="background-color:#1a9850" |Superior primary endpoint
+|-
+|[https://doi.org/10.1182/blood-2008-08-174946 DiPersio et al. 2009 (AMD3100-3102)]
+|2005-02-04 to 2006-07-07
+| style="background-color:#1a9851" |Phase 3 (E-esc)
+|[[#G-CSF_monotherapy|G-CSF]]
 | style="background-color:#1a9850" |Superior primary endpoint
 |-
 |}
+<div class="toccolours" style="background-color:#b3e2cd">
 ====Growth factor therapy====
 *[[Plerixafor (Mozobil)]]
 *[[:Category:Granulocyte_colony-stimulating_factors|G-CSF]]
+'''One course'''
+</div></div>
 ===References===
-# '''Study 3101:''' DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009 Oct 1;27(28):4767-73. Epub 2009 Aug 31. [https://doi.org/10.1200/JCO.2008.20.7209 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19720922 PubMed]
+# '''AMD3100-3102:''' DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL, Maziarz RT, Hosing C, Früehauf S, Horwitz M, Cooper D, Bridger G, Calandra G; 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009 Jun 4;113(23):5720-6. Epub 2009 Apr 10. [https://doi.org/10.1182/blood-2008-08-174946 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19363221/ PubMed] [https://clinicaltrials.gov/study/NCT00103662 NCT00103662]
+# '''Study 3101:''' DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E, Nademanee A, McCarty J, Bridger G, Calandra G; 3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol. 2009 Oct 1;27(28):4767-73. Epub 2009 Aug 31. [https://doi.org/10.1200/JCO.2008.20.7209 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19720922/ PubMed] [https://clinicaltrials.gov/study/NCT00103610 NCT00103610]
 [[Category:Stem cell mobilization regimens]]
 [[Category:Site-agnostic regimens]]

Difference between revisions of "Stem cell mobilization regimens"

Revision as of 23:41, 28 May 2024

Stem cell mobilization, all lines of therapy

CAD & G-CSF

Regimen

Preceding treatment

Chemotherapy

Glucocorticoid therapy

Growth factor therapy

Subsequent treatment

References

Cyclophosphamide & G-CSF

Regimen variant #1

Chemotherapy

Growth factor therapy

Regimen variant #2

Chemotherapy

Growth factor therapy

References

Cytarabine & G-CSF

Regimen variant #1, 2000 mg/m2 x 8

Chemotherapy

Growth factor therapy

Regimen variant #2, 3000 mg/m2 x 2

Chemotherapy

Growth factor therapy

References

Cytarabine, Ifosfamide, G-CSF

Regimen

Chemotherapy

Growth factor therapy

References

Cytarabine & Etoposide (CYVE) & G-CSF

Regimen

Chemotherapy

Growth factor therapy

References

DCEP & G-CSF

Regimen

Glucocorticoid therapy

Chemotherapy

Supportive therapy

References

EAR & G-CSF

Regimen

Preceding treatment

Chemotherapy

Targeted therapy

Supportive therapy

Subsequent treatment

References

IGEV & G-CSF

Regimen

Chemotherapy

Glucocorticoid therapy

Supportive therapy

References

DexaBEAM & G-CSF

Regimen

Glucocorticoid therapy

Chemotherapy

Growth factor therapy

References

Motixafortide & G-CSF

Regimen

Growth factor therapy

References

Plerixafor & G-CSF

Regimen

Growth factor therapy

References

Navigation menu

Search

Regimen variant #1, 2000 mg/m² x 8

Regimen variant #2, 3000 mg/m² x 2